newsfilter
← Latest News
GlobeNewswire·

Oyster Point Pharma Reports First Quarter 2022 Financial Results and Recent Business Highlights

TYRVAYA® Nasal Spray Net Product Revenue of $2.7 Million in Q1'22 Approximately 19,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Over 4,500 Unique Eye Care Professionals Expansion of Commercial Coverage for TYRVAY